JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beers, R. A.
Right arrow Articles by Camporesi, E. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beers, R. A.
Right arrow Articles by Camporesi, E. M.
Anesth Analg 2000;91:1420-1425
© 2000 International Anesthesia Research Society


AMBULATORY ANESTHESIA

A Comparison of the Cost-Effectiveness of Remifentanil Versus Fentanyl as an Adjuvant to General Anesthesia for Outpatient Gynecologic Surgery

Richard A. Beers, MD, J. Robert Calimlim, MD, Emmanuel Uddoh, MD, Barbara F. Esposito, RN, and Enrico M. Camporesi, MD

Department of Anesthesiology, Upstate Medical University, Syracuse, NY

Address correspondence and reprint requests to Richard A. Beers, MD, Department of Anesthesiology, Upstate Medical University, 750 E. Adams Street, Syracuse, NY 13210. Address e-mail to beersr{at}mail.hscsyr.edu

The unique pharmacokinetic properties of remifentanil make it a potentially useful adjuvant during general anesthesia for ambulatory surgery. Fentanyl, inexpensive and easy to administer, is the most common opioid used for this purpose. As an adjuvant to general anesthesia for outpatient gynecologic surgery, we questioned if remifentanil was cost-effective as an alternative to fentanyl. Thirty-four patients undergoing gynecologic laparoscopy or hysteroscopy were prospectively and randomly assigned to a standard practice (n = 18) or a study (n = 16) group. Standard practice patients received fentanyl (3 µg/kg) before induction; study patients received remifentanil by continuous infusion (0.5 µg · kg · min-1 at induction, then 0.2 µg · kg · min-1). Sevoflurane was titrated to a Bispectral index value of 40–55. We investigated recovery profiles, patient and health care professional satisfaction, and drug costs . The incidence of rescue antiemetic treatment (2 of 16 vs 8 of 18; P = 0.013) and the nausea visual analog scale scores during second stage recovery (0.2 vs 0.6; P = 0.044) were more frequent in the study group. However, the incidence of intraoperative adverse events and other postoperative sequelae, recovery times, pain and nausea visual analog scale scores, opioid analgesic dosage requirements in the postanesthetic care unit, and satisfaction survey responses were similar between groups. Perioperative drug costs per patient were $17.72 more in the remifentanil (vs fentanyl) group.

Implications: As an opioid adjuvant to general anesthesia for outpatient gynecologic laparoscopy and hysteroscopy, the benefits of remifentanil did not offset its added cost as compared with fentanyl.







Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins and Stanford University Libraries' HighWire Press®. Copyright 2000 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2000 by the International Anesthesia Research Society.